Tumor shrinkage was observed at study end in 17/17 treatment-naïve patients whose dose interval of LAN was extended from the initial 4-weekly dosing based on GH normalization (≤ 2.5 μg/L) (Table 1) [52]. This evidence concerns the gene GH1 and neoplasm.